Long position on GBPCAD bit late to posting as price has already moved away from my entry. Bullish engulfing candle supports the initial idea.
Anticipating $1.30 to deliver by Tuesday EOD. Been a successful week since last post. +300 points. Happy Holidays :)
First Wave BioPharma is a clinical-stage biopharmaceutical company that specializes in the development of targeted, non-systemic therapies for gastrointestinal diseases. 52 Week Range 1.27 - 26.30 Now the price is close to all time low and looks like a buy opportunity!
I think antiaging stocks will be the new FAANGS in 5 to 10 years. Immortality here, on earth, is the next frontier for the medicine. CohBar is developing mitochondria-based therapeutics for the treatment of chronic and age-related diseases. On 11/12/2021 Cantor Fitzgerald brokerage Initiated Coverage on CWBR with an Overweight rating and a price target of...
Astra Space, Inc. (ASTR) to deploy its first satellite in orbit for the National Aeronautics and Space Administration (NASA) in January 2022. At this price before this big upcoming catalyst, this looks like a great buying opportunity! My short term price target is 11.8usd. Looking forward to read your opinion about it.
More than 15K calls on BKKT are expiring today. and those are the calls from the last month only. The strike price varies from 14 to 75usd. The price of the stock is now 9.08usd. Yesterday we saw a volume of 32mil. Besides the 32mil, Dark Pool Prints were 33Mil. Dark pools are private exchanges not accessible by the investing public. Dark pools facilitate block...
Yesterday, JMP Securities Initiated Coverage on Quoin Pharmaceuticals, Ltd. (QNRX) with a Market Outperform rating and a price target of 8usd. Quoin Pharmaceuticals (NASDAQ: QNRX) is positioned to deliver the first FDA-approved treatment for Netherton Syndrome, a devastating disorder which affects 1 in every 200,000 people worldwide. This month, QNRX Signed...
James Sapirstein Chairman, President and CEO of First Wave BioPharma, Inc.: "We now have development- and clinical-stage programs that span six GI indications with significant market size opportunities, including: COVID-19-related GI infections (estimated at $10 billion, for COVID-19 related anti-virals); ulcerative colitis, ulcerative proctitis and ulcerative...
NeuroSense Therapeutics Ltd. (NRSN) listed yesterday only 2,000,000 shares on NASDAQ Capital at a price of $6.00. Due to the extremely low liquidity, high volatility is expected. I rarely see 2Mil shares float in a stock which also dropped from 6usd to 3.83usd in the pre-market right now. I rate this a Buy!
Department of Defense Awards C3 AI $500 Million on a new five-year Production-Other Transaction Agreement. The stock bounced from all time low. My price target is the $47.5 resistance.
Fibonacci support and indicators suggest a potential turnaround.
Ardelyx , Inc. ARDX had one of the the highest the out of the money call options, due to the fact they plan to launch IBSRELA, the company's FDA approved treatment for irritable bowel syndrome with constipation (IBS-C) in adults, in the second quarter of 2022, that has a potential peak in revenue greater than 500mil per year. Since ARDX’s Market Cap is only...
Rumble platform growth from 1.6 million average monthly active users in Q3 2020 to a record 36 million average monthly active users in Q3 2021. 44 million monthly active users in August 2021. CFVI merger transaction values Rumble at an enterprise value of $2.1 billion. Do you see more upside from here?
BBIGVinco Ventures stock looks to have big potential on this trend reversal. They own aspiring TikTok competitor Lomotif. My price target is 5.5usd by year`s end and 15usd in 2022. Looking forward to read your opinion about it!
MongoDB's fiscal third-quarter revenue increased 50% year over year. Revenue growth rate increasing from 39% growth in the first quarter of fiscal 2022 to 44% in fiscal Q2 and now 50% in fiscal Q3. MongoDB's 50% revenue growth put total revenue for fiscal Q3 at $227 million. This was far beyond analysts' average forecast for revenue of $205 million during the...
Here is my analysis on CRO and some buy limits you must-have set.
Hi everyone. Please support my work by clicking the LIKE button (If you liked). Everything on the chart. Follow me on TRADING View, if you don't want to miss my next analysis or signals. It's not financial advice. Do not Forget, always make your own research before to trade my ideas! Good luck everyone Thank you!
Recently, on 11/19/2021 Morgan Stanley brokerage Boosted the Price Target for CVX Chevron Corporation to Overweight from $149.00 to $155.00. Jim Cramer also talked about a buy opportunity in Chevron shares yesterday, since they have enough money to pay the dividends for the next year, 5.36 (4.57%), and the demand for oil is still there. The Price per Earnings...